Comparison of biochemical markers of bone resorption in patients with metabolic and malignant bone diseases

被引:8
|
作者
Withold, W
Friedrich, W
Reinauer, H
机构
[1] Inst. F. Klin. Chem. L., Heinrich-Heine-Univ. Düsseldorf, D-40225 Düsseldorf
关键词
bone metastases; renal transplantation; telopeptides; pyridinium cross-links;
D O I
10.1177/000456329603300504
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The clinical usefulness of the urinary excretion of three bone resorption markers is compared in patients after renal transplantation and in tumour patients with and without bone metastases. The markers were the 3-hydroxypyridinium derivatives pyridinoline and deoxypyridinoline (pyridinium cross-links; measured by a polyclonal enzyme immunoassay), the cross-linked N-telopeptid-to-helix domain of type I collagen and the destruction products of type I collagen metabolism crossreacting with a peptide sequence of the alpha(1)-chain of the C-terminal telopeptide region of type I collagen (CrossLaps(TM)). In patients receiving renal transplantation the discriminating power of N-telopeptides was superior to that of pyridinium cross-links and CrossLaps(TM), with Z scores (number of SDs from apparently healthy controls) of 6.61, 2.17 and 1.35, respectively. However, the pyridinium cross-links were the only markers for bone resorption which showed a significant increase with time (P<0.001). Receiver operating-characteristic analysis for discriminating patients with bone metastases from those without revealed that the accuracy was 0.81 for pyridinium cross-links, 0.76 for the N-telopeptides and 0.61 for CrossLaps(TM). The discriminating power for patients with bone metastases was higher for pyridinium cross-links and N-telopeptides than for CrossLaps(TM), with Z scores (number of SDs from patients without bone metastases) of 4.38, 3.00 and 1.24, respectively. Linear correlation coefficients for the different markers were between + 0.35 and + 0.65 in patients receiving renal transplants, and between + 0.58 and + 0.84 in patients with bone metastases. In conclusion, in patients with metabolic and malignant bone diseases there are marked differences in the diagnostic performance of different biochemical markers of bone resorption. It is suggested that this may reflect the different facets of bone resorption or the different metabolic fates of the marker substances examined.
引用
收藏
页码:421 / 427
页数:7
相关论文
共 50 条
  • [1] Clinical performances of biochemical markers of bone resorption in metabolic bone diseases.
    Dorizzi, RM
    Bertoldo, F
    Zanini, M
    Caputo, M
    Gasperi, E
    Furlan, F
    CLINICAL CHEMISTRY, 1997, 43 : 636 - 636
  • [2] Comparison of bone resorption markers in metabolic bone disease.
    Sokoll, LJ
    Levine, MA
    Kroll, MH
    Chan, DW
    CLINICAL CHEMISTRY, 1996, 42 (06) : 105 - 105
  • [3] Biochemical markers of bone resorption
    Robins, SP
    BIOMARKERS OF DISEASE: AN EVIDENCE-BASED APPROACH, 2002, : 122 - 132
  • [4] The clinical use of bone resorption markers in patients with malignant bone disease
    Coleman, RE
    CANCER, 2002, 94 (10) : 2521 - 2533
  • [5] URINARY BONE-RESORPTION MARKERS IN PATIENTS WITH METABOLIC BONE DISORDERS
    OHISHI, T
    KUSHIDA, K
    TAKAHASHI, M
    KAWANA, K
    YAGI, K
    KAWAKAMI, K
    HORIUCHI, K
    INOUE, T
    BONE, 1994, 15 (01) : 15 - 20
  • [6] Biochemical markers of bone resorption and formation in breast cancer patients with bone metastases
    Vrbanec, D
    Belev, B
    Martinovic, I
    Plestina, S
    ANNALS OF ONCOLOGY, 1998, 9 : 24 - 24
  • [7] Metastatic bone disease and the role of biochemical markers of bone metabolism in benign and malignant diseases
    Coleman, RE
    CANCER TREATMENT REVIEWS, 2001, 27 (03) : 133 - 135
  • [8] Comparison of markers of bone formation and resorption in prostate cancer patients to predict bone metastasis
    Akimoto, S
    Furuya, Y
    Akakura, K
    Ito, H
    ENDOCRINE JOURNAL, 1998, 45 (01) : 97 - 104
  • [9] BIOCHEMICAL MARKERS IN BONE-DISEASES
    LEONSANZ, M
    LARRODERA, L
    REVISTA CLINICA ESPANOLA, 1993, 193 (09): : 494 - 502
  • [10] PYRIDINIUM CROSS-LINKS IN URINE - SPECIFIC MARKERS OF BONE-RESORPTION IN METABOLIC BONE-DISEASES
    SEIBEL, MJ
    ZIPF, A
    ZIEGLER, R
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1994, 119 (25-26) : 923 - 929